Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215559) titled 'A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes' on Oct. 9.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Obesity
Overweight
Diabetes Mellitus, Type 2
Intervention:
Drug: Macupatide
Drug: Eloralintide
Drug: Macupatide Placebo
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 2025
Target Sa...